IN8bio to Present at July Investor and Scientific Conferences
June 30, 2022 16:15 ET
|
IN8bio, Inc
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences
June 08, 2022 08:00 ET
|
IN8bio, Inc
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
June 06, 2022 07:00 ET
|
IN8bio, Inc
100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two patients, to date, having exceeded their expected overall survival (OS). An unmethylated GBM patient...
IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
May 17, 2022 07:00 ET
|
IN8bio, Inc
IN8bio recently unveiled expansion of its DeltEx gamma-delta T cell platform capabilities to include induced pluripotent stem cells (iPSCs).Yesterday, at the American Society for Gene & Cell...
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 08:00 ET
|
IN8bio, Inc
Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate encouraging data.INB-100 patient update at European...
IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting
May 05, 2022 08:00 ET
|
IN8bio, Inc
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today...
IN8bio to Present at May Investor and Scientific Conferences
May 04, 2022 08:00 ET
|
IN8bio, Inc
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies...
IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments
April 13, 2022 08:30 ET
|
IN8bio, Inc
Urvashi Patel, Ph.D., as Vice President, Regulatory AffairsStacey Bilinski, as Vice President, Clinical Operations NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a...
IN8bio to Present at April Investor and Scientific Conferences
April 05, 2022 16:15 ET
|
IN8bio, Inc
NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
March 28, 2022 08:00 ET
|
IN8bio, Inc
All three patients with high-risk or relapsed acute-myeloid leukemia (AML) dosed to-date with INB-100 demonstrated durable remissions at 23.3, 21.0, and 9.3 months post-BMT, respectively. Immune...